You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePiroxicam
Accession NumberDB00554  (APRD01187)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem]
Structure
Thumb
Synonyms
4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid
Feldene
Piroxicam
Piroxicamum
Pyroxycam
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-piroxicam-cap 10mgCapsule10 mgOralAltimed Pharma Inc.1997-09-242004-08-03Canada
Alti-piroxicam-cap 20mgCapsule20 mgOralAltimed Pharma Inc.1995-12-312004-08-03Canada
Dom-piroxicamCapsule20 mgOralDominion Pharmacal1999-10-252016-10-25Canada
Dom-piroxicamSuppository10 mgRectalDominion Pharmacal1995-12-312016-10-25Canada
Dom-piroxicamCapsule10 mgOralDominion PharmacalNot applicable2016-10-25Canada
Dom-piroxicamSuppository20 mgRectalDominion Pharmacal1995-12-312016-10-25Canada
FeldeneCapsule10 mg/1OralPfizer Laboratories Div Pfizer Inc1994-05-25Not applicableUs
FeldeneCapsule20 mg/1OralREMEDYREPACK INC.2012-09-26Not applicableUs
FeldeneCapsule20 mg/1OralPfizer Laboratories Div Pfizer Inc1994-05-25Not applicableUs
Feldene Cap 10mgCapsule10 mgOralPfizer Canada Inc1981-12-312002-09-06Canada
Feldene Cap 20mgCapsule20 mgOralPfizer Canada Inc1981-12-312002-07-25Canada
Feldene Sup 10mgSuppository10 mgRectalPfizer Canada Inc1986-12-311999-08-10Canada
Feldene Sup 20mgSuppository20 mgRectalPfizer Canada Inc1986-12-312002-07-25Canada
FexicamSuppository20 mgRectalTechnilab Pharma Inc.1998-08-172004-08-03Canada
Gen-piroxicam - Cap 20mgCapsule20 mgOralGenpharm Ulc1995-12-312010-08-04Canada
Gen-piroxicam-cap 10mgCapsule10 mgOralGenpharm Ulc1995-12-312010-08-04Canada
Nu-pirox Cap 10mgCapsule10 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-pirox Cap 20mgCapsule20 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Penta-piroxicam CapsulesCapsule20 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-piroxicam CapsulesCapsule10 mgOralPentapharm Ltd.Not applicableNot applicableCanada
PiroxicamCapsule10 mg/1OralGreenstone LLC2014-03-03Not applicableUs
PiroxicamCapsule20 mg/1OralGreenstone LLC2014-03-03Not applicableUs
Piroxicam Capsules 10mgCapsule10 mgOralPrempharm Inc1997-01-052005-08-05Canada
Piroxicam Capsules 20mgCapsule20 mgOralPrempharm Inc1997-01-052005-08-05Canada
PMS-piroxicamCapsule20 mgOralPharmascience Inc1996-12-312016-10-28Canada
PMS-piroxicamCapsule10 mgOralPharmascience Inc1996-12-312016-10-28Canada
PMS-piroxicam Suppositories -20mgSuppository20 mgRectalPharmascience Inc1995-12-312016-10-28Canada
PMS-piroxicam Suppositories-10mgSuppository10 mgRectalPharmascience Inc1995-12-312016-10-28Canada
Pro-piroxicam Cap 10mgTablet10 mgOralPro Doc Limitee1987-12-312010-07-13Canada
Pro-piroxicam Cap 20mgCapsule20 mgOralPro Doc Limitee1987-12-312010-07-13Canada
Rho-piroxicam - 10mg CapCapsule10 mgOralRhodiapharm Inc1995-12-311998-08-05Canada
Rho-piroxicam - Cap 20mgCapsule20 mgOralRhodiapharm Inc1995-12-311998-08-05Canada
Teva-piroxicamCapsule20 mgOralTeva Canada Limited1986-12-31Not applicableCanada
Teva-piroxicamCapsule10 mgOralTeva Canada Limited1986-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Piroxicam Cap 10mgCapsule10 mgOralApotex Inc1986-12-31Not applicableCanada
Apo Piroxicam Cap 20mgCapsule20 mgOralApotex Inc1986-12-31Not applicableCanada
FeldeneCapsule20 mg/1OralKeltman Pharmaceuticals Inc.2007-09-18Not applicableUs
PiroxicamCapsule10 mg/1OralNostrum Laboratories, Inc.2010-01-05Not applicableUs
PiroxicamCapsule10 mg/1OralGolden State Medical Supply, Inc.2010-01-05Not applicableUs
PiroxicamCapsule20 mg/1OralNorthstar Rx LLC2016-02-15Not applicableUs
PiroxicamCapsule10 mg/1OralPACK Pharmaceuticals, LLC2010-06-15Not applicableUs
PiroxicamCapsule20 mg/1OralH.J. Harkins Company, Inc.2012-04-16Not applicableUs
PiroxicamCapsule10 mg/1OralAvera Mc Kennan Hospital2015-11-10Not applicableUs
PiroxicamCapsule20 mg/1OralSTAT Rx USA LLC2011-10-07Not applicableUs
PiroxicamCapsule20 mg/1OralAphena Pharma Solutions Tennessee, Llc1994-01-26Not applicableUs
PiroxicamCapsule20 mg/1OralDIRECT RX2014-01-01Not applicableUs
PiroxicamCapsule20 mg/1OralAv Kare, Inc.2012-11-28Not applicableUs
PiroxicamCapsule20 mg/1OralRebel Distributors Corp2009-11-12Not applicableUs
PiroxicamCapsule20 mg/1OralPhysicians Total Care, Inc.1994-10-06Not applicableUs
PiroxicamCapsule20 mg/1OralNostrum Laboratories, Inc.2010-01-05Not applicableUs
PiroxicamCapsule20 mg/1OralGolden State Medical Supply, Inc.2010-01-05Not applicableUs
PiroxicamCapsule10 mg/1OralMylan Pharmaceuticals Inc.2016-09-30Not applicableUs
PiroxicamCapsule20 mg/1OralPACK Pharmaceuticals, LLC2010-06-15Not applicableUs
PiroxicamCapsule10 mg/1OralH.J. Harkins Company, Inc.2012-04-16Not applicableUs
PiroxicamCapsule10 mg/1OralTeva Pharmaceuticals Usa, Inc.1994-10-19Not applicableUs
PiroxicamCapsule10 mg/1OralNivagen Pharmaceuticals, Inc2016-02-152016-11-30Us
PiroxicamCapsule20 mg/1OralREMEDYREPACK INC.2011-04-122016-10-13Us
PiroxicamCapsule10 mg/1OralSun Pharmaceutical Industries, Inc.1993-03-12Not applicableUs
PiroxicamCapsule20 mg/1OralPd Rx Pharmaceuticals, Inc.1994-01-26Not applicableUs
PiroxicamCapsule10 mg/1OralRebel Distributors Corp2009-11-12Not applicableUs
PiroxicamCapsule20 mg/1OralRebel Distributors Corp2010-01-05Not applicableUs
PiroxicamCapsule20 mg/1Oralbryant ranch prepack2010-01-05Not applicableUs
PiroxicamCapsule20 mg/1OralMylan Pharmaceuticals Inc.2016-09-30Not applicableUs
PiroxicamCapsule10 mg/1OralSTAT Rx USA LLC2010-11-02Not applicableUs
PiroxicamCapsule20 mg/1OralA S Medication Solutions Llc2010-01-05Not applicableUs
PiroxicamCapsule20 mg/1OralTeva Pharmaceuticals Usa, Inc.1994-01-26Not applicableUs
PiroxicamCapsule20 mg/1OralLake Erie Medical DBA Quality Care Products LLC1994-01-26Not applicableUs
PiroxicamCapsule20 mg/1OralNivagen Pharmaceuticals, Inc2016-02-152016-11-30Us
PiroxicamCapsule10 mg/1OralREMEDYREPACK INC.2013-03-202016-10-21Us
PiroxicamCapsule20 mg/1OralSun Pharmaceutical Industries, Inc.1993-03-12Not applicableUs
PiroxicamCapsule10 mg/1OralNorthstar Rx LLC2016-02-15Not applicableUs
PiroxicamCapsule10 mg/1OralRebel Distributors Corp2010-01-05Not applicableUs
PiroxicamCapsule10 mg/1Oralbryant ranch prepack2010-01-05Not applicableUs
PiroxicamCapsule20 mg/1OralA S Medication Solutions2010-01-05Not applicableUs
PiroxicamCapsule20 mg/1OralSTAT Rx USA LLC2010-11-02Not applicableUs
PiroxicamCapsule10 mg/1OralPhysicians Total Care, Inc.2005-01-21Not applicableUs
PiroxicamCapsule10 mg/1OralAv Kare, Inc.2013-06-27Not applicableUs
PiroxicamCapsule20 mg/1OralUnit Dose Services2010-01-05Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BruxicamNot Available
DolonexNot Available
ErazonNot Available
GeldèneNot Available
ImprontalNot Available
RoxamBosnalijek
RoxidenNot Available
SasulenNot Available
SolocalmNot Available
TrastNot Available
Brand mixtures
NameLabellerIngredients
TherafeldaminePhysician Therapeutics Llc
SaltsNot Available
Categories
UNII13T4O6VMAM
CAS number36322-90-4
WeightAverage: 331.346
Monoisotopic: 331.062676609
Chemical FormulaC15H13N3O4S
InChI KeyQYSPLQLAKJAUJT-UHFFFAOYSA-N
InChI
InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
IUPAC Name
4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1λ⁶,2-benzothiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O
Pharmacology
IndicationFor treatment of osteoarthritis and rheumatoid arthritis.
Structured Indications
PharmacodynamicsPiroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.
Mechanism of actionThe antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Related Articles
AbsorptionWell absorbed following oral administration.
Volume of distribution
  • 0.14 L/kg
Protein bindingNot Available
Metabolism

Renal

SubstrateEnzymesProduct
Piroxicam
5'-HydroxypiroxicamDetails
Route of eliminationPiroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a piroxicam dose is excreted unchanged. However, a substantial portion of piroxicam elimination occurs by hepatic metabolism. Piroxicam is excreted into human milk.
Half life30 to 86 hours
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Piroxicam Action PathwayDrug actionSMP00077
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Piroxicam is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Piroxicam is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Piroxicam is combined with 5-androstenedione.Experimental, Illicit
AbciximabPiroxicam may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Piroxicam can be increased when it is combined with Abiraterone.Approved
AcebutololPiroxicam may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Aceclofenac.Approved
AcenocoumarolPiroxicam may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinPiroxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Piroxicam.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alendronic acid.Approved
AliskirenPiroxicam may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololPiroxicam may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Piroxicam.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Amcinonide.Approved
AmikacinPiroxicam may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmiloridePiroxicam may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Piroxicam can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Piroxicam.Approved
AmrubicinPiroxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodPiroxicam may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Piroxicam is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Anisodamine.Investigational
annamycinPiroxicam may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Antipyrine.Approved
Antithrombin III humanPiroxicam may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Piroxicam may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanPiroxicam may increase the anticoagulant activities of Apixaban.Approved
ApramycinPiroxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Piroxicam is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Piroxicam can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinPiroxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinPiroxicam may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanPiroxicam may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololPiroxicam may decrease the antihypertensive activities of Arotinolol.Approved
AtenololPiroxicam may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Piroxicam.Approved
BalsalazidePiroxicam may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminPiroxicam may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololPiroxicam may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Piroxicam.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Piroxicam.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Piroxicam.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Betamethasone.Approved, Vet Approved
BetaxololPiroxicam may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Betulinic Acid.Investigational
BevantololPiroxicam may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Piroxicam.Approved, Investigational
BisoprololPiroxicam may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPiroxicam may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololPiroxicam may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bucillamine.Investigational
BucindololPiroxicam may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Budesonide.Approved
BufuralolPiroxicam may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanidePiroxicam may decrease the diuretic activities of Bumetanide.Approved
BupranololPiroxicam may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Piroxicam.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Piroxicam.Experimental
CapecitabineThe metabolism of Piroxicam can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Piroxicam.Approved
CarbamazepineThe metabolism of Piroxicam can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Piroxicam.Approved
CarprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololPiroxicam may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPiroxicam may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Celecoxib.Approved, Investigational
CeliprololPiroxicam may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Piroxicam can be increased when it is combined with Ceritinib.Approved
CertoparinPiroxicam may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Piroxicam.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Piroxicam.Approved
CholecalciferolThe metabolism of Piroxicam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Piroxicam.Approved
CinoxacinPiroxicam may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinPiroxicam may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidPiroxicam may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clonixin.Approved
ClopidogrelThe metabolism of Piroxicam can be decreased when combined with Clopidogrel.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Piroxicam.Vet Approved
ClotrimazoleThe metabolism of Piroxicam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Piroxicam is combined with Curcumin.Investigational
CyclosporinePiroxicam may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Piroxicam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Piroxicam is combined with D-Limonene.Investigational
Dabigatran etexilatePiroxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Piroxicam can be decreased when it is combined with Dabrafenib.Approved
DalteparinPiroxicam may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPiroxicam may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinPiroxicam may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Piroxicam can be increased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Piroxicam is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Piroxicam can be decreased when combined with Delavirdine.Approved
DesirudinPiroxicam may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Piroxicam.Approved
DextranPiroxicam may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Piroxicam may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Piroxicam may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Piroxicam may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Piroxicam.Approved, Vet Approved
DicoumarolPiroxicam may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Piroxicam is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Piroxicam.Approved
DihydrostreptomycinPiroxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Piroxicam.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Piroxicam.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Piroxicam.Approved
DoxorubicinPiroxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenonePiroxicam may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Piroxicam is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ebselen.Investigational
Edetic AcidPiroxicam may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPiroxicam may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Piroxicam can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Piroxicam.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Piroxicam.Approved
EnoxacinPiroxicam may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinPiroxicam may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Piroxicam is combined with Epirizole.Approved
EpirubicinPiroxicam may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenonePiroxicam may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Piroxicam.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Piroxicam.Approved
EquileninThe risk or severity of adverse effects can be increased when Piroxicam is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Equilin.Approved
EsmololPiroxicam may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Estrone sulfate.Approved
Etacrynic acidPiroxicam may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Piroxicam.Approved, Investigational
Ethyl biscoumacetatePiroxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Piroxicam can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Piroxicam is combined with exisulind.Investigational
FelodipineThe metabolism of Piroxicam can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Piroxicam.Vet Approved
FleroxacinPiroxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Piroxicam.Approved, Withdrawn
FloxuridineThe metabolism of Piroxicam can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with fluasterone.Investigational
FluconazoleThe metabolism of Piroxicam can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fludrocortisone.Approved
FluindionePiroxicam may increase the anticoagulant activities of Fluindione.Investigational
FlumequinePiroxicam may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Piroxicam can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Piroxicam.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Piroxicam can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Piroxicam can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Piroxicam.Approved, Nutraceutical, Vet Approved
FondaparinuxPiroxicam may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPiroxicam may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Piroxicam.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Piroxicam.Approved
FosphenytoinThe metabolism of Piroxicam can be increased when combined with Fosphenytoin.Approved
FramycetinPiroxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemidePiroxicam may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexatePiroxicam may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinPiroxicam may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPiroxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Piroxicam.Approved, Withdrawn
GemfibrozilThe metabolism of Piroxicam can be decreased when combined with Gemfibrozil.Approved
GemifloxacinPiroxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinPiroxicam may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinPiroxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APiroxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinPiroxicam may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Piroxicam is combined with HE3286.Investigational
HeparinPiroxicam may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Higenamine.Investigational
HirulogPiroxicam may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Piroxicam is combined with HMPL-004.Investigational
HydralazinePiroxicam may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Piroxicam.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Piroxicam.Approved
Hygromycin BPiroxicam may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Piroxicam is combined with Icatibant.Approved
IdarubicinPiroxicam may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxPiroxicam may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Piroxicam.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Piroxicam.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Piroxicam.Approved
IndenololPiroxicam may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Piroxicam can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Piroxicam.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Indoprofen.Withdrawn
INNO-206Piroxicam may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Piroxicam can be decreased when combined with Irbesartan.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Piroxicam is combined with Istaroxime.Investigational
KanamycinPiroxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Piroxicam can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Piroxicam.Approved
LabetalolPiroxicam may decrease the antihypertensive activities of Labetalol.Approved
LapatinibThe metabolism of Piroxicam can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Piroxicam.Approved, Investigational
LeflunomideThe metabolism of Piroxicam can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinPiroxicam may increase the anticoagulant activities of Lepirudin.Approved
LevobunololPiroxicam may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPiroxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Piroxicam.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Piroxicam.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Piroxicam.Approved
LomefloxacinPiroxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved
LopinavirThe metabolism of Piroxicam can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lornoxicam.Approved
LosartanThe metabolism of Piroxicam can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Piroxicam can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Piroxicam.Approved, Investigational
LumacaftorThe serum concentration of Piroxicam can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Piroxicam.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Piroxicam.Approved
ME-609The risk or severity of adverse effects can be increased when Piroxicam is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mefenamic acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meloxicam.Approved, Vet Approved
MesalazinePiroxicam may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Piroxicam is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Piroxicam.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piroxicam.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Methylprednisolone.Approved, Vet Approved
MetipranololPiroxicam may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Piroxicam.Approved
MetoprololPiroxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamidePiroxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneThe serum concentration of Piroxicam can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Piroxicam.Approved
MizoribineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Piroxicam.Approved
MometasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Piroxicam.Approved
MoxifloxacinPiroxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nabumetone.Approved
NadololPiroxicam may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPiroxicam may increase the anticoagulant activities of Nadroparin.Approved
NafamostatPiroxicam may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Naftifine.Approved
Nalidixic AcidPiroxicam may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Piroxicam is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Piroxicam is combined with NCX 4016.Investigational
NeaminePiroxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinPiroxicam may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinPiroxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nepafenac.Approved
NetilmicinPiroxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Piroxicam can be decreased when combined with Nicardipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Piroxicam can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nitroaspirin.Investigational
NorfloxacinPiroxicam may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinPiroxicam may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Piroxicam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Olopatadine.Approved
OlsalazinePiroxicam may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Piroxicam.Investigational
OmeprazoleThe metabolism of Piroxicam can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Orgotein.Vet Approved
OtamixabanPiroxicam may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxaprozin.Approved
OxprenololPiroxicam may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Parecoxib.Approved
ParomomycinPiroxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinPiroxicam may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPiroxicam may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololPiroxicam may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfatePiroxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Piroxicam.Approved
PhenindionePiroxicam may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Piroxicam can be increased when combined with Phenobarbital.Approved
PhenprocoumonPiroxicam may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Piroxicam can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Piroxicam.Approved, Investigational
PindololPiroxicam may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Piroxicam can be decreased when combined with Pioglitazone.Approved, Investigational
PirarubicinPiroxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanidePiroxicam may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pirfenidone.Investigational
PlicamycinPiroxicam may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Piroxicam.Approved
PractololPiroxicam may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Piroxicam.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Piroxicam can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Piroxicam can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Propacetamol.Approved
PropranololPiroxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Piroxicam.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Piroxicam.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Piroxicam.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Piroxicam.Vet Approved
Protein CPiroxicam may increase the anticoagulant activities of Protein C.Approved
Protein S humanPiroxicam may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePiroxicam may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPiroxicam may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Piroxicam is combined with PTC299.Investigational
PuromycinPiroxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Piroxicam can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Piroxicam.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Piroxicam.Approved
QuinineThe metabolism of Piroxicam can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Piroxicam can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Piroxicam.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Piroxicam.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Resveratrol.Experimental, Investigational
ReviparinPiroxicam may increase the anticoagulant activities of Reviparin.Approved
RibostamycinPiroxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Piroxicam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Piroxicam can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Risedronate.Approved, Investigational
RitonavirThe metabolism of Piroxicam can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanPiroxicam may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe metabolism of Piroxicam can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinPiroxicam may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Piroxicam.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Piroxicam.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Piroxicam.Investigational
SecobarbitalThe metabolism of Piroxicam can be increased when combined with Secobarbital.Approved, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Piroxicam is combined with Seratrodast.Approved, Investigational
SildenafilThe metabolism of Piroxicam can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinPiroxicam may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe metabolism of Piroxicam can be decreased when combined with Sorafenib.Approved, Investigational
SotalolPiroxicam may decrease the antihypertensive activities of Sotalol.Approved
SP1049CPiroxicam may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinPiroxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinPiroxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Piroxicam.Approved
SpironolactonePiroxicam may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Piroxicam is combined with SRT501.Investigational
StiripentolThe metabolism of Piroxicam can be decreased when combined with Stiripentol.Approved
StreptomycinPiroxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinPiroxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Piroxicam can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Piroxicam can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazinePiroxicam may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Piroxicam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Sulindac.Approved
SulodexidePiroxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Piroxicam.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Suprofen.Approved, Withdrawn
TacrolimusPiroxicam may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Piroxicam.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Piroxicam.Approved
TamoxifenThe metabolism of Piroxicam can be decreased when combined with Tamoxifen.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Piroxicam.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Piroxicam.Approved, Investigational
TemafloxacinPiroxicam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Piroxicam.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Piroxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tepoxalin.Vet Approved
TeriflunomideThe metabolism of Piroxicam can be decreased when combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Piroxicam can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Piroxicam can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tiludronate.Approved, Vet Approved
TimololPiroxicam may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tixocortol.Approved
TobramycinPiroxicam may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Piroxicam can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Piroxicam.Approved
TorasemidePiroxicam may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Piroxicam.Approved
TranilastThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Piroxicam.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Piroxicam.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Triamcinolone.Approved, Vet Approved
TriamterenePiroxicam may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Piroxicam.Approved, Vet Approved
TrimethoprimThe metabolism of Piroxicam can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Trisalicylate-choline.Approved
TrovafloxacinPiroxicam may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Piroxicam.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Piroxicam can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinPiroxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Piroxicam can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Piroxicam.Approved
VoriconazoleThe metabolism of Piroxicam can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinPiroxicam may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPiroxicam may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Piroxicam may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Piroxicam can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zileuton.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zomepirac.Withdrawn
ZorubicinPiroxicam may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Take with food. Avoid alcohol.
References
Synthesis Reference

Paul D. Weeks, “3-Hydroxy 2-methyl benzisothiazolines as intermediates in production of piroxicam.” U.S. Patent US4376204, issued April, 1982.

US4376204
General ReferencesNot Available
External Links
ATC CodesM02AA07S01BC06M01AC01
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (74.3 KB)
MSDSDownload (73.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9898
Blood Brain Barrier-0.9659
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5786
P-glycoprotein inhibitor INon-inhibitor0.7285
P-glycoprotein inhibitor IINon-inhibitor0.7453
Renal organic cation transporterNon-inhibitor0.9437
CYP450 2C9 substrateSubstrate0.6437
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7356
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.9086
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8789
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8709
Ames testNon AMES toxic0.8767
CarcinogenicityNon-carcinogens0.7612
BiodegradationNot ready biodegradable0.923
Rat acute toxicity3.1545 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9589
hERG inhibition (predictor II)Non-inhibitor0.8311
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Akorn inc
  • Pfizer laboratories div pfizer inc
  • Egis pharmaceuticals
  • Genpharm pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nostrum laboratories inc
  • Roxane laboratories inc
  • Scs pharmaceuticals
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg
CapsuleOral20 mg
SuppositoryRectal10 mg
SuppositoryRectal20 mg
CapsuleOral10 mg/1
CapsuleOral20 mg/1
TabletOral10 mg
Kit
Prices
Unit descriptionCostUnit
Piroxicam powder13.16USD g
Akten 3.5% drops7.5USD ml
Feldene 20 mg capsule4.93USD capsule
Feldene 10 mg capsule2.82USD capsule
Piroxicam 20 mg capsule2.69USD capsule
Pms-Piroxicam 20 mg Suppository1.82USD suppository
Piroxicam 10 mg capsule1.44USD capsule
Apo-Piroxicam 20 mg Capsule0.75USD capsule
Novo-Pirocam 20 mg Capsule0.75USD capsule
Nu-Pirox 20 mg Capsule0.75USD capsule
Apo-Piroxicam 10 mg Capsule0.43USD capsule
Gen-Piroxicam 10 mg Capsule0.43USD capsule
Novo-Pirocam 10 mg Capsule0.43USD capsule
Nu-Pirox 10 mg Capsule0.43USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point198-200 °CPhysProp
water solubility23 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.06AVDEEF,A (1997)
logS-4.16ADME Research, USCD
Caco2 permeability-4.45ADME Research, USCD
pKa6.3SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP2.2ALOGPS
logP0.6ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.76ChemAxon
pKa (Strongest Basic)3.79ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity87.04 m3·mol-1ChemAxon
Polarizability32.27 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassNot Available
Direct ParentBenzothiazines
Alternative Parents
Substituents
  • N-arylamide
  • Benzothiazine
  • Aminopyridine
  • Imidolactam
  • Benzenoid
  • Pyridine
  • Ortho-thiazine
  • Heteroaromatic compound
  • Vinylogous acid
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057 ]
  2. Bugajski J, Glod R, Gadek-Michalska A, Bugajski AJ: Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):795-809. [PubMed:11785774 ]
  3. Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22. [PubMed:11153163 ]
  4. Raju J, Bird RP: Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam. Mol Cell Biochem. 2002 Feb;231(1-2):139-46. [PubMed:11952155 ]
  5. Veiga AP, Duarte ID, Avila MN, da Motta PG, Tatsuo MA, Francischi JN: Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004 Oct 22;75(23):2807-17. [PubMed:15464832 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057 ]
  2. Bugajski J, Glod R, Gadek-Michalska A, Bugajski AJ: Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):795-809. [PubMed:11785774 ]
  3. Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22. [PubMed:11153163 ]
  4. Raju J, Bird RP: Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam. Mol Cell Biochem. 2002 Feb;231(1-2):139-46. [PubMed:11952155 ]
  5. Veiga AP, Duarte ID, Avila MN, da Motta PG, Tatsuo MA, Francischi JN: Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004 Oct 22;75(23):2807-17. [PubMed:15464832 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  4. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
  5. Tsuda M, Sekine T, Takeda M, Cha SH, Kanai Y, Kimura M, Endou H: Transport of ochratoxin A by renal multispecific organic anion transporter 1. J Pharmacol Exp Ther. 1999 Jun;289(3):1301-5. [PubMed:10336520 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  3. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, Cha SH, Sekine T, Sakthisekaran D, Endou H: Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75. [PubMed:12063169 ]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23